Ocular Therapeutix, Inc. (OCUL)

Market Cap	397.62M
Revenue (ttm)	51.49M
Net Income (ttm)	-71.04M
Shares Out	77.51M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	366,192
Open	5.35
Previous Close	5.29
Day's Range	5.12 - 5.40
52-Week Range	2.57 - 6.53
Beta	1.27
Analysts	Buy
Price Target	12.09 (+135.21%)
Earnings Date	May 8, 2023

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2014
• Employees: 228
• Stock Exchange: NASDAQ
• Ticker Symbol: OCUL

Financial Performance

In 2022, OCUL's revenue was $51.49 million, an increase of 18.32% compared to the previous year's $43.52 million. Losses were -$71.04 million, 984.1% more than in 2021.

Analyst Forecast

According to 13 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $12.09, which is an increase of 135.21% from the latest price.

Price Target

$12.09

(135.21% upside)

Analyst Consensus: Buy